Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 2/20 | 0.62 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.62 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.50 |
| ▸ | ERN1 | O75460 | 2/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7323609 | 0.97 | TRIM24 (0.58) | TYRTRIM24TRIM33MAPTMEN1 | |
| SCHEMBL10580362 | 0.95 | NR5A1 (0.58) | TYRTRIM24TRIM33MAPTMEN1 | |
| SCHEMBL4067042 | 0.95 | NR5A1 (0.58) | TYRTRIM24TRIM33MAPTMEN1 | |
| SCHEMBL7763425 | 0.95 | NR5A1 (0.58) | TYRTRIM24TRIM33MAPTMEN1 | |
| SCHEMBL1813069 | 0.95 | NR5A1 (0.58) | TYRTRIM24TRIM33MAPTMEN1 | |
| SCHEMBL7763936 | 0.95 | NR5A1 (0.58) | TYRTRIM24TRIM33MAPTMEN1 | |
| SCHEMBL19025099 | 0.93 | TYR (0.62) | TYRTRIM24TRIM33MAPTMEN1 | |
| SCHEMBL7761736 | 0.89 | NR5A1 (0.51) | TYRTRIM24TRIM33MEN1ALDH1A1 | |
| SCHEMBL7763959 | 0.88 | NR5A1 (0.54) | TYRTRIM24TRIM33MAPTLTA4H | |
| SCHEMBL20339391 | 0.87 | TYR (0.63) | TYRTRIM24TRIM33MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170065719-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2017-03-09 | — | — | US | disclosed |
| US-20170051000-A1 | C-TERMINAL HSP90 INHIBITORS | REATA PHARMACEUTICALS, INC. | 2017-02-23 | — | — | US | disclosed |
| WO-2017030814-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | Arvinas, Inc. (US) | 2017-02-23 | — | — | WO | disclosed |
| US-9422320-B2 | C-terminal HSP90 inhibitors | UNIVERSITY OF KANSAS (US) | 2016-08-23 | — | — | US | disclosed |
| US-9278915-B2 | Agonists of GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2016-03-08 | — | — | US | disclosed |
| US-9075014-B2 | pH-responsive fluorescent false neurotransmitters and their use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-07-07 | — | — | US | disclosed |
| US-9045405-B2 | Compounds and methods for preparation of diarylpropanes | UNIGEN, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-9012412-B2 | Dual SGLT1/SGLT2 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-21 | — | — | US | disclosed |
| US-20150057240-A1 | C-TERMINAL HSP90 INHIBITORS | REATA PHARMACEUTICALS, INC. | 2015-02-26 | — | — | US | disclosed |
| US-20140256657-A1 | DUAL SGLT1/SGLT2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-11 | — | — | US | disclosed |
| US-7446127-B2 | Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders | SK HOLDINGS CO, LTD. (KR) | 2008-11-04 | — | — | US | disclosed |
| WO-2008128961-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | METHYLGENE, INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| WO-2007118137-A1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2007-10-18 | — | — | WO | disclosed |
| US-20070244155-A1 | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2007-10-18 | — | — | US | disclosed |
| WO-2007106469-A2 | BICYCLIC CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| US-20070106095-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| WO-2005030704-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2005-04-07 | — | — | WO | disclosed |
| US-3966755-A | OPTICAL BRIGHTENERS | CIBA-GEIGY CORPORATION (US) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256657-A1 | DUAL SGLT1/SGLT2 INHIBITORS | SLC5A1, SLC5A2, GLP1R | TYR 4112/4885TRIM24 2776/4885TRIM33 2887/4885 |
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | TYR 3509/4885TRIM24 1615/4885TRIM33 1027/4885 |
| US-20070244155-A1 | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders | GOT2, PC, GOT1 | TYR 2035/4885TRIM24 4485/4885TRIM33 4777/4885 |
| US-20070106095-A1 | Vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | TYR 2659/4885TRIM24 487/4885TRIM33 993/4885 |
| US-20150057240-A1 | C-TERMINAL HSP90 INHIBITORS | HSP90AB2P, HSP90AB1, HSP90B1 | TYR 3688/4885TRIM24 1292/4885TRIM33 1024/4885 |
| US-20170051000-A1 | C-TERMINAL HSP90 INHIBITORS | HSP90AB2P, HSP90AB1, HSP90B1 | TYR 3688/4885TRIM24 1292/4885TRIM33 1024/4885 |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | TYR 3509/4885TRIM24 1615/4885TRIM33 1027/4885 |
| US-20170065719-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | TYR 4100/4885TRIM24 369/4885TRIM33 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.